The Hydrocortisone vs Pasireotide in Reducing Pancreatic Surgery Complications Noninferiority Trial: Comparing Apples and Pears?

JAMA Surg. 2020 Oct 1;155(10):994-995. doi: 10.1001/jamasurg.2020.1998.

Authors

Alfred Adiamah¹, Anisa Kushairi¹, Dhanwant Gomez¹

Affiliation

¹ Department of Hepatobiliary and Pancreatic Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, England.

PMID: 32667633
DOI: 10.1001/jamasurg.2020.1998

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Hydrocortisone
Malus*
Pancreatic Fistula
Pyrus*
Somatostatin / analogs & derivatives

Substances

Somatostatin
pasireotide
Hydrocortisone